ProfileGDS5678 / 1448989_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 82% 82% 80% 82% 83% 80% 78% 78% 82% 85% 85% 85% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0504983
GSM967853U87-EV human glioblastoma xenograft - Control 26.0254782
GSM967854U87-EV human glioblastoma xenograft - Control 35.9834482
GSM967855U87-EV human glioblastoma xenograft - Control 45.7926880
GSM967856U87-EV human glioblastoma xenograft - Control 55.9915982
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8233983
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.537180
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4115678
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3836178
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.043582
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4071885
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4344885
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4300685
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7541888